Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2015 · 10-Q
Revenue$1.87M$1.87M+95.2% vs Q3 2014 Net Income-$13.63M-$13.63MN/M vs Q3 2014 EPS Diluted-$0.18-$0.18N/M vs Q3 2014 Gross Profit$1,874,000+95.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,561,000N/M Free Cash Flowderived-$11,770,000N/M Margins · derivedGross margin100.0%−0.0 pt vs Q3 2014
Operating margin-912.7%+351.6 pt vs Q3 2014
Net margin-727.1%+134.1 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end